These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35528958)

  • 1. A pilot study assessing the similarity between core outcome sets and outcomes included in health technology assessments.
    Cox P; R Williamson P; Dodd S
    F1000Res; 2021; 10():1084. PubMed ID: 35528958
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing the impact of a research funder's recommendation to consider core outcome sets.
    Hughes KL; Kirkham JJ; Clarke M; Williamson PR
    PLoS One; 2019; 14(9):e0222418. PubMed ID: 31518375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do the findings of case series studies vary significantly according to methodological characteristics?
    Dalziel K; Round A; Stein K; Garside R; Castelnuovo E; Payne L
    Health Technol Assess; 2005 Jan; 9(2):iii-iv, 1-146. PubMed ID: 15588556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.
    Dundar Y; Dodd S; Dickson R; Walley T; Haycox A; Williamson PR
    Health Technol Assess; 2006 Feb; 10(5):iii-iv, ix-145. PubMed ID: 16487455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of databases other than medline for rapid health technology assessments.
    Lorenzetti DL; Topfer LA; Dennett L; Clement F
    Int J Technol Assess Health Care; 2014 Apr; 30(2):173-8. PubMed ID: 24774535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HTA core model: a novel method for producing and reporting health technology assessments.
    Lampe K; Mäkelä M; Garrido MV; Anttila H; Autti-Rämö I; Hicks NJ; Hofmann B; Koivisto J; Kunz R; Kärki P; Malmivaara A; Meiesaar K; Reiman-Möttönen P; Norderhaug I; Pasternack I; Ruano-Ravina A; Räsänen P; Saalasti-Koskinen U; Saarni SI; Walin L; Kristensen FB;
    Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():9-20. PubMed ID: 20030886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging health technology assessment and healthcare quality improvement using international consortium of health outcomes measurement standard sets.
    Kalf RRJ; Zuidgeest M; Delnoij DMJ; Bouvy ML; Goettsch WG
    Int J Technol Assess Health Care; 2021 Dec; 38(1):e6. PubMed ID: 36317685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supporting the Use of Health Technology Assessments by Decision-Makers.
    Polisena J; Lavis JN; Juzwishin D; McLean-Veysey P; Graham ID; Harstall C; Martin J
    Healthc Policy; 2015 May; 10(4):10-5. PubMed ID: 26142355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Representation of published core outcome sets in practice guidelines.
    Rhodes S; Dodd S; Deckert S; Vasanthan L; Qiu R; Rohde JF; Florez ID; Schmitt J; Nieuwlaat R; Kirkham J; Williamson PR
    J Clin Epidemiol; 2024 May; 169():111311. PubMed ID: 38423401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluations of public health interventions produced by health technology assessment agencies: A mapping review and analysis by type and evidence content.
    Cyr PR; Jain V; Chalkidou K; Ottersen T; Gopinathan U
    Health Policy; 2021 Aug; 125(8):1054-1064. PubMed ID: 34112508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment on cervical cancer screening, 2000-2014.
    Lahue BJ; Baginska E; Li SS; Parisi M
    Int J Technol Assess Health Care; 2015 Jan; 31(3):171-80. PubMed ID: 26179276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the hta core model with a national health technology assessment report.
    Pasternack I; de Groot I; Kleijnen S; Polman P
    Int J Technol Assess Health Care; 2014 Nov; 30(5):530-5. PubMed ID: 25747563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More than half of systematic reviews have relevant core outcome sets.
    Saldanha IJ; Dodd S; Gorst SL; Williamson PR
    J Clin Epidemiol; 2021 Aug; 136():168-179. PubMed ID: 33974970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the HTA core model: experiences from two pilot projects.
    Pasternack I; Anttila H; Mäkelä M; Ikonen T; Räsänen P; Lampe K; van Brabandt H; Cleemput I; de Laet C; Marchetti M; Refolo P; Sacchini D; Kunz R; Nordmann A; Lühmann D; Freyschuss B;
    Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():21-7. PubMed ID: 20030887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study.
    Meregaglia M; Ciani O; Banks H; Salcher-Konrad M; Carney C; Jayawardana S; Williamson P; Fattore G
    BMC Med Res Methodol; 2020 Feb; 20(1):41. PubMed ID: 32103725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines.
    Messina J; Grainger DL
    Patient; 2012; 5(3):199-211. PubMed ID: 22804831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary survey on the influence of rapid health technology assessments.
    Hailey D
    Int J Technol Assess Health Care; 2009 Jul; 25(3):415-8. PubMed ID: 19619362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organizational and patient-related assessments in HTAs: state of the art.
    Lee A; Skött LS; Hansen HP
    Int J Technol Assess Health Care; 2009 Oct; 25(4):530-6. PubMed ID: 19845983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance.
    Aiyegbusi OL; di Ruffano LF; Retzer A; Newsome PN; Buckley CD; Calvert MJ
    Trials; 2022 Jan; 23(1):42. PubMed ID: 35033186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology.
    Chassany O; Engen AV; Lai L; Borhade K; Ravi M; Harnett J; Chen CI; Quek RG
    Future Oncol; 2022 Sep; 18(29):3323-3334. PubMed ID: 36053168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.